NEW YORK, March 25, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA, highlighting the Company's Diabetes Management Application as being suitable and safe for children and young people. In its recommendation, ORCHA mentioned the value of Dario's app in helping parents monitoring their child's diabetes information. The ORCHA team is part of NHS England's National Innovation Accelerator program and supports many NHS and local government organizations to drive the uptake of digital health among their populations.
"This recognition from ORCHA further validates the use of our platform technology for remote patient monitoring for chronic care management, especially in these challenging times," said Erez Raphael, CEO of DarioHealth. "The ongoing COVID-19 pandemic has made it difficult for millions of patients worldwide with chronic disease to access healthcare though conventional channels. Our technology provides patients with easy to use software, testing supplies and personalized coaching around each user's data, enabling them to manage their disease without leaving the safety of their home."
Base on ORCHA's criteria for evaluating smartphone technologies, the organization has included Dario Diabetes Management on a list of "Coronavirus" apps eligible for recognition, based on the following attributes:
- Managing mental health, including anxiety,
- Conditions such as asthma and diabetes.
ORCHA highlighted the value of healthcare apps in keeping children and young people engaged with their health and wellbeing, as well as relieving pressure on the NHS.
ORCHA is the World's leading health app evaluation and advisor organization. It helps governments, health and social care organizations to choose and deliver health apps that will safely make the biggest impact in terms of improving outcomes. ORCHA's tools help health professionals to prescribe and monitor usage of health apps. They are proven to increase take-up and self-management of conditions.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel.
For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, Dario is using forward-looking statements in this press release when it discusses the benefits of Dario's technology to patients. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Content & Communications Manager
Investor Relations Contact:
SOURCE DarioHealth Corp.